Figure 8.
hiPSC‐EV target the PI3K/AKT pathway. A) Gene expression of PTEN, CDKN1A (p21WAF/Cip1), and CCND1 (cyclin D1) on HUVEC treated with hiPSC‐EV for 24 h. B) Western blot for PTEN and quantification of PTEN expression relative to B‐ACTIN. C) Western blot for total AKT and active phosphorylated forms (P‐AKT Thr308 and P‐AKT Ser473). Relative quantification of P‐AKT was performed against total AKT. Data are mean ± SD, n = 3. Relative ratios were calculated in relation to the untreated control (ECGM‐2 only). Significance tested by a one‐sample t‐test. *p < 0.05.